STOCKS TELEGRAPH

Tag: CLOV stock

  • Clover Health (CLOV) Stock Rallies In After-Market Following Subsidiary’s Contract Win

    Clover Health (CLOV) Stock Rallies In After-Market Following Subsidiary’s Contract Win

    The stock price of Clover Health Investments, Corp. (NASDAQ: CLOV) experienced a large increase subsequent to the news of a noteworthy multi-year contract obtained by its subsidiary, Counterpart Health, Inc. In after-hours trading, CLOV shares saw a strong recovery, rising 19.20% to reach $2.98, following a normal trading session loss of 4.94%, ending at $2.50.

    Clover Health-Subsidiary Formed A Strategic Partnership

    The Iowa Clinic, P.C. is a highly regarded multispecialty healthcare practice in the United States. Counterpart Health, Inc., a well-known AI-driven physician enablement platform and a subsidiary of Clover Health, just engaged into a multi-year deal with them. Through this relationship, Counterpart Health is able to advance its planned national development by designating The Iowa Clinic as one of its cornerstone customers in the Midwest.

    CLOV Offering Integration of AI-Powered Tools in Healthcare

    Under this agreement, clinicians associated with The Iowa Clinic’s Medicare Advantage and Medicare Shared Savings Program patients will utilize Counterpart Assistant, an advanced cloud-based software platform developed by Counterpart Health. This platform will also be extended to The Iowa Clinic’s clinically integrated network partners across the Midwest. Counterpart Health is set to receive a per-member, per-month fee along with potential incentive payments tied to the achievement of specific care management objectives.

    Counterpart Assistant is distinguished by its ability to leverage clinical data to drive improved patient outcomes. It stands out as a solution in the healthcare sector because of its user-friendly design, which is suited to the requirements of working professionals, and its interaction with current processes. Over a thousand doctors worldwide presently use this AI-enabled platform, which was first created by Clover Health and aids the early identification and management of chronic illnesses.

    Impact on Healthcare Outcomes

    Counterpart Health’s platform utilizes real-time insights from more than a hundred data sources and over one hundred machine learning models, enabling healthcare providers to identify, diagnose, and treat costly chronic diseases earlier. The platform has proven effective in reducing medical costs, as evidenced by the significant improvement in medical cost ratios for Clover Health’s Medicare Advantage plans. This success underscores the value of Counterpart Assistant in managing Medicare risk and enhancing patient care outcomes.

  • Clover Health Investments Corp. (CLOV) Soars After Hours on Beat Quarterly Earnings

    The medicare advantage insurer, Clover Health Investments Corp. (CLOV) posted its Q1 fiscal 2022 earnings on May 9, 2022. The beat quarterly earnings had the stock rebound in the after-hours to reach $2.79 per share. Thus, after a loss of 10.41% during regular trading, CLOV added 15.77% in the after-hours session. The prior session had the stock valued at $2.41 apiece at the close.

    Source: AZZ

    CLOV’s Earnings Analysis

    For the first quarter of 2022, the company reported total revenues of $874.4 million while the comparable figure stands at $200.3 million. On top of the huge YOY improvement, the quarterly revenue surpassed the consensus estimate by 7.23%.

    Moreover, CLOV posted a net loss of $75.3 million while the adjusted EBITDA loss was $71.8 million for the quarter. Thus, the company came out with a quarterly loss of 19 cents a share while analysts were expecting a loss of 24 cents per share for the quarter.

    Additionally, lives under Clover Assistant Management shot up by a humungous 550% YOY while live unique users on Clover Assistant went up by 43% YOY.

    Therefore, the beat earnings and revenue on top of huge growth in Clover Assistant’s popularity shows CLOV is off to a strong start in 2022. However, keeping the pace up throughout the year might prove challenging due to the wider economic situation and instability.

    CLOV’s Future Expectations

    According to the interim CFO Mark Herbers, despite the overall market conditions, the company is cautiously optimistic for 2022. Focusing on sustainable and intelligent growth, CLOV expects its total revenue for 2022 to be somewhere between $3.0 and $3.4 billion. Hence, the full-year revenue guidance remains in line with the consensus estimate of $3.28 billion.

    Furthermore, the company expects its insurance membership to deliver a growth rate of 26-27% and insurance MCR between 95-99% for 2022. The adjusted operating expenses are anticipated to fall between $330 and $345 million.

    What Else?

    In addition, CLOV also announced a new appointment on Monday as it has been working on bolstering its management team. Following the recent appointments of CTO and General Counsel, the company announced Aric Sharp as divisional CEO of Value-Based Care for Clover.

    Conclusion

    Following the better-than-expected quarterly report and an upbeat outlook despite the dire situation of the wider market, CLOV rallied big in the after-hours on Monday. The company also announced a new management appointment along with the earnings release.

  • Clover Health Investments Corp. (CLOV) stock Soars After Hours on Q4 2021 Earnings

    On February 23, Clover Health Investments Corp. (CLOV) declared its financial results for Q4 and fiscal 2021. Consequently, the stock recovered in the after-hours and became bullish.

    During the regular session, the stock plunged down to its new 52-week low of $1.95. With a loss of 1.47%, CLOV closed the session in the red at $2.01. The day saw a heavy volume of 33.92 million which was 233% of its usual. Following the announcement, the stock rebounded to gain 14.93% in the after-hours session. Hence, the stock was trading at $2.31 per share at an after-hours volume of 13.9 million on Wednesday.

    The healthcare insurance services provider, Clover Health Investments Corp. was founded in 2014. As of now, the company’s 330.48 million outstanding shares trade at a market capitalization of $964.52 million. In the past five days, CLOV stock has lost 18,29% while losing 45.97% year to date. Moreover, the stock subtracted a huge value of 80.56% last year.

    CLOV’s 2021 Financial Report

    In Q4 2021, the company had total revenue of $432.0 million which marked a huge increase of 160% YOY. This compares to $166.2 million in Q4 2020.

    Furthermore, the company reported a net loss of $187.2 million for Q4 2021, against $126.4 million in the year-ago period.

    Additionally, the non-GAAP normalized adjusted EBITDA was a loss of $68.5 million in Q4 2021 against $41.5 million in the prior-year period.

    Liver under Clover Assistant Management delivered a 223% YOY growth on December 31, 2021.

    2022 Guidance

    For fiscal 2022, CLOV expected total revenues of $3.0-$3.4 billion with adjusted operating expenses of $330 to $345 million.

    The company expects Medicare Advantage membership to increase by 26-27% in fiscal 2022.

    CLOV Company News

    On February 10, the company announced that it will be participating in Citi’s 2022 Virtual Healthcare Conference in February. The company’s CEO, Vivek Garipalli, and President, Andrew Toy would be presenting at the conference on February 24, 2022.

    On January 10, the company provided updates on its Medicare Advantage (MA) membership growth. According to the company, MA membership has increased by 25% as compared to the beginning of 2021. Thus, it has outpaced the overall industry growth average of 10% YOY approx. In addition, CLOV had entered 2022 above its previous guidance of 82,000 lives for MA memberships.

    Conclusion

    CLOV stock had been falling down severely as it reached a new 52-week low on Wednesday. But the after-hours session brought good news in the form of beat earnings. Finally giving a breathing chance to the stock. Therefore, the stock made a comeback in the after-hours on Wednesday.